Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Bracelet-1 90 day exclusivity should be over x Feb 2023

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Nov 23, 2022 2:28pm

264 Views

Post# 35122842

RE:RE:RE:RE:The Bracelet-1 90 day exclusivity should be over x Feb 2023

Do you agree with the fact that, whenever the 90 day exclusivity started, if neither Roche nor PFE make an offer before the exclusivity ends then an offer is unlikely from either party? Roche and Pfizer know NOW what pela brings to the table...if they aren't a present time negotiating or tabling offers then the may not be interested. I think a Roche offer comes late this yr, early Jan...my opinion.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario